

1 **The Role of X Chromosome in Alzheimer’s Disease Genetics.**

2 **Authors:** Michael E. Belloy^{1-3,*}, PhD, Yann Le Guen^{1,4,*}, PhD, Ilaria Stewart¹, BA, Joachim Herz⁵, MD, Richard
3 Sherva⁶, PhD, Rui Zhang⁷, MS, Victoria Merritt^{8,9}, PhD, Matthew S. Panizzon^{9,10}, PhD, Richard L. Hauger^{8,9,10},
4 MD, the VA Million Veteran Program, J. Michael Gaziano^{11,12}, MD, Mark Logue^{6,7,13,14}, PhD, Valerio
5 Napolioni^{15,#}, PhD, and Michael D. Greicius^{1,#}, MD MPH.

6
7 ¹Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA

8 ²NeuroGenomics and Informatics Center, Washington University School of Medicine, St.Louis, MO, USA

9 ³Department of Neurology, Washington University School of Medicine, St.Louis, MO, USA

10 ⁴Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

11 ⁵Center for Translational Neurodegeneration Research, Department of Molecular Genetics University of Texas
12 Southwestern Medical Center at Dallas, Dallas, TX, USA

13 ⁶Biomedical Genetics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA

14 ⁷National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, MA, USA

15 ⁸Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, CA, USA

16 ⁹Department of Psychiatry, University of California San Diego, La Jolla, CA, USA

17 ¹⁰Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla, CA, USA

18 ¹¹Million Veteran Program (MVP) Coordinating Center, VA Boston Healthcare System, Boston, MA, USA

19 ¹²Division of Aging, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA, USA

20 ¹³Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA

21 ¹⁴Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA

22 ¹⁵School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, Italy

23
24 *Equal contribution; #Equal contribution

26 **Corresponding Author**

27 Michael E. Belloy

28 Department of Neurology

29 NeuroGenomics and Informatics Center (NGI)

30 Washington University in Saint Louis (WashU)

31 4444 Forest Park Ave, St. Louis, MO 63108, USA

32 Phone: (+1) 314-747-2608

33 Email: belloy@wustl.edu

34 **Key points**

35 **Question:** Does the X chromosome play a role in the genetics of Alzheimer’s Disease (AD)?

36 **Findings:** In a genetic meta-analysis across 1,152,284 individuals, several X chromosome loci were
37 associated with AD. Four loci showed evidence of shared genetic associations between AD risk and
38 regulation of nearby gene expression in brain tissue. The top association signal was intronic on *SLC9A7*
39 and linked to its expression.

40 **Meaning:** We performed the first large-scale X chromosome-wide association study of AD and prioritized
41 *SLC9A7* as a novel risk locus. This study significantly advances our knowledge of AD genetics and provides
42 novel biological drug targets.

43 **Abstract**

44 **Importance:** The X chromosome has remained enigmatic in Alzheimer's disease (AD), yet it makes up 5%
45 of the genome and carries a high proportion of genes expressed in the brain, making it particularly
46 appealing as a potential source of unexplored genetic variation in AD.

47 **Objectives:** Perform the first large-scale X chromosome-wide association study (XWAS) of AD. Primary
48 analyses are non-stratified, while secondary analyses evaluate sex-stratified effects.

49 **Design:** Meta-analysis of genetic association studies in case-control, family-based, population-based, and
50 longitudinal AD-related cohorts from the US Alzheimer's Disease Genetics Consortium (ADGC) and
51 Alzheimer's Disease Sequencing Project (ADSP), the UK Biobank (UKB), the Finnish health registry
52 (FinnGen), and the US Million Veterans Program (MVP). Risk for AD evaluated through case-control logistic
53 regression analyses. Data were analyzed between January 2023 and March 2024.

54 **Setting:** Genetic data available from high-density single-nucleotide polymorphism (SNP) microarrays and
55 whole-genome sequencing (WGS). Summary statistics for multi-tissue expression and protein quantitative
56 trait loci (QTL) available from published studies, enabling follow-up genetic colocalization analyses.

57 **Participants:** 1,629,863 eligible participants were selected from referred and volunteer samples, of which
58 477,596 were excluded for analysis exclusion criteria. Number of participants who declined to participate
59 in original studies was not available.

60 **Main Outcome and Measures:** Risk for AD (odds ratio; OR) with 95% confidence intervals (CI).
61 Associations were considered at X-chromosome-wide (P -value $<1e-5$) and genome-wide (P -value $<5e-8$)
62 significance.

63 **Results:** Analyses included 1,152,284 non-Hispanic White European ancestry subjects (57.3% females),
64 including 138,558 cases. 6 independent genetic loci passed X-chromosome-wide significance, with 4
65 showing support for causal links between the genetic signal for AD and expression of nearby genes in
66 brain and non-brain tissues. One of these 4 loci passed conservative genome-wide significance, with its
67 lead variant centered on an intron of *SLC9A7* (OR=1.054, 95%-CI=[1.035, 1.075]) and colocalization
68 analyses prioritizing both the *SLC9A7* and nearby *CHST7* genes.

69 **Conclusion and Relevance:** We performed the first large-scale XWAS of AD and identified the novel
70 *SLC9A7* locus. *SLC9A7* regulates pH homeostasis in Golgi secretory compartments and is anticipated to

71 have downstream effects on amyloid beta accumulation. Overall, this study significantly advances our
72 knowledge of AD genetics and may provide novel biological drug targets.

73 **Introduction**

74 The X chromosome has remained enigmatic, not just in AD, but in the broader field of genome-wide
75 association studies. It is typically excluded due to technical challenges and power limitations because of
76 its complex inheritance pattern¹. The X chromosome however makes up 5% of the genome and carries a
77 high proportion of genes expressed in the brain. Additionally, it may contribute to the well-established
78 higher prevalence of AD in women relative to men². We thus set out to fill in this gap by performing the
79 first meta-analysis of XWAS conducted on various publicly available AD-related cohorts, as well as multiple
80 biobanks where AD phenotypes were available. To ensure maximal power, this study was designed as a
81 large-scale discovery combining all available samples.

82 **Methods**

83 An in-depth overview of all methodologies is provided in the **eMethods**. The current study followed
84 STREGA reporting guidelines. Participants or their caregivers provided written informed consent in the
85 original studies. The current study protocol was granted an exemption by the Stanford Institutional
86 Review Board because the analyses were carried out on “de-identified, off-the-shelf” data; therefore,
87 additional informed consent was not required.

88 **Data Ascertainment**

89 Case-control, family-based, and longitudinal AD genetic cohorts from the ADGC and ADSP (release-3)
90 were available through public repositories, with genetic data from SNP microarrays and WGS (**eTable1-**
91 **2**)^{3,4}. These cohorts contributed clinically diagnosed AD cases (40.0% pathology verified; **eTable3**).
92 Analyses in UKB, FinnGen, and MVP used genetic data from SNP microarrays⁵⁻⁸. UKB data and FinnGen
93 summary results (v10) were publicly available. UKB contributed health-registry-confirmed AD cases and
94 proxy Alzheimer’s disease-and-dementia (ADD) cases; FinnGen contributed health-registry-confirmed AD
95 cases; MVP contributed health-registry-confirmed and proxy ADD cases.

96 **Quality Control and Processing**

97 ADGC and ADSP data underwent extensive quality control (QC) and imputation to the TOPMed
98 reference panel (**eTable4-5**). Specific consideration was given to X-chromosome QC as in prior work (cf.
99 **eMethods**)⁹. Genetic data processing for UKB, FinnGen, and MVP followed cohort-specific protocols⁵⁻⁸.
100 Non-Hispanic White, European ancestry cases and controls, carrying XX or XY with concordant self-
101 reported sex and ages >60 years (>18 and median=63 in FinnGen), were retained for analyses (**eFigure1**;
102 **eTable3**). Variants were filtered using cohort-specific minor allele frequency (MAF) criteria, which on
103 average correspond to MAF>0.05% (**eTable5**).

104 **X chromosome Considerations**

105 X chromosome analyses considered non-pseudoautosomal regions. Genotype encoding was 0/2 in men
106 (XY) and 0/1/2 in women (XX), following a random X chromosome inactivation (XCI) model in women. In
107 UKB, most cases were proxy cases, i.e. family history of ADD in first-degree relatives. This proxy approach
108 has been established to replicate AD autosomal genetic risk factors and be adaptable to XWAS¹⁰. To
109 maximize power, the health-registry and proxy status were unified into a single phenotype for which

110 association coefficients were adjusted onto a regular case-control scale (**eTable6-7**). After rescaling, UKB
111 showed consistent coefficient distributions with ADGC+ADSP (**eFigure2**). A similar approach was used in
112 MVP, but in line with MVP protocols, analyses were separated for health-registry and proxy phenotypes⁷.

113 **Statistical Analyses**

114 XWAS evaluated case-control logistic regressions on AD risk, adjusting for sex, age, technical covariates,
115 and genetic principal components (capturing population stratification) as applicable per dataset. Mixed
116 models to include related subjects were used in ADGC, ADSP, UKB (LMM-BOLT v2.4)¹¹, and FinnGen
117 (Regenie)⁶. Association results across datasets were combined through fixed effects inverse-variance
118 weighted meta-analyses. Primary analyses were non-stratified. Secondary analyses were sex-stratified,
119 and conducted across ADGC, ADSP, and UKB. Association results were considered at the X-chromosome-
120 wide (P-value<1e-5) and conservative genome-wide thresholds (P-value<5e-8). Sex effects were
121 evaluated through heterogeneity tests and considered significant at P<0.05. Evidence for escape from XCI
122 was evaluated by comparing variant beta coefficients derived from men and women-stratified XWAS
123 (ratio=1 indicates escape; ratio=2 indicates no escape)¹².

124 **Genetic Colocalization**

125 To identify potentially causal genes in associated risk loci, statistical colocalization was evaluated
126 between the local genetic association signal for AD and the genetic association signal for molecular traits
127 such as expression levels of genes within that locus (R-v.4.2.1, *coloc*)¹³. We leveraged public datasets
128 where quantitative trait loci (QTL) for expression and protein levels were available for the X chromosome
129 in brain and non-brain tissues (cf. **eMethods**).

130 Results

131 The study design is provided in **Figure1A**. 1,152,284 individuals (138,558 cases: 15,081 clinically
132 diagnosed cases, 41,091 health-registry-confirmed cases, and 82,386 proxy cases) were included in the
133 XWAS (**eTable3**). There was no sign of genomic inflation (**eFigure3**). We associated 2 rare (MAF<1%) lead
134 variants in the *NLGN4X* and *MID1* loci, and 4 common lead variants in the *SLC9A7*, *ZNF280C*, *ARGRG4*, and
135 *MTM1* loci (**Table1**; locus zoom and forest plots in **eFigures4-5**). All common variant loci showed
136 colocalization for at least one nearby gene in brain tissue (**Table2**; **eTable8**). The overall top association
137 signal (cross-cohort allele frequencies in **eTable9**), intronic on *SLC9A7*, passed conservative significance
138 criteria and showed colocalization for several genes, most notably *SLC9A7* and *CHST7*. Colocalization plots
139 for top prioritized genes are in **eFigures6-10**.

140 The *ZNF280C* and *ARGRG4* lead variants showed evidence for escape from XCI, while the *MID1* variant
141 appeared female-specific (**eTable10**). Sex-stratified XWAS only revealed 1 X-chromosome-wide
142 significant, female-specific rare variant association without colocalization support (**eFigure11**, **eTable11**)
143 and indicated that evidence for escape from XCI was apparent only for a few common, small effect size
144 variants (**eFigure12**).

145 Discussion

146 We performed an XWAS of AD in 1,152,284 individuals, making this the largest genetic association
147 study of AD to date¹⁴. The top signal showed support for a causal link between the genetic regulation of
148 *SLC9A7* or *CHST7* expression and AD risk. *CHST7* encodes a chondroitin 6-sulfotransferase that confers
149 negatively charged sulfate groups to glycosaminoglycans, which may relate to promoting tau fibrillization
150 and spreading¹⁵. Notably, *SLC9A7* (a.k.a *NHE7*) is a paralog of *SLC9A6* (a.k.a *NHE6*), previously implicated
151 in experimental work as an X-linked AD modifying gene¹⁶. These are highly conserved genes that regulate
152 pH homeostasis in Golgi secretory compartments and endosomes and might thus be expected to
153 contribute to increased amyloid accumulation across aging when their expression levels are increased (a
154 detailed background and rationale are provided in **Appendix-A**). In line with this expectation, QTL data
155 support that the top risk allele is associated with increased expression of *SLC9A7* in brain tissue, increasing
156 expression by 17-44% for an active allele (**eTable12**). Although the *SLC9A7* top variant has a small effect
157 size (OR=1.054, 95%-CI=[1.035, 1.075]), given this relatively small effect on *SLC9A7* expression in the brain,
158 it may be that more substantial reduction or pharmacological inhibition of *SLC9A7* would prove to be an
159 effective therapeutic strategy for AD.

160 Despite this study's formidable sample size, only the *SLC9A7* locus reached conservative significance
161 criteria with a small effect size, suggesting the X chromosome contributes relatively little to AD
162 prevalence. In addition, only 2 lead variants of small effect size indicated escape from XCI and only 1 rare
163 lead variant appeared female-specific, such that these XWAS results have little bearing on sex-stratified
164 AD prevalence. Similarly, sex-stratified XWAS did not reveal striking results, which would have been
165 expected if the X chromosome played a significant role in the observations that 2/3 of AD patients across
166 the lifespan are women². Overall, our results suggest that while the X chromosome plays only a small role
167 in the population prevalence of AD, the specific pathways highlighted here open the door to novel
168 pathogenic pathways and associated drug targets.

169 Limitations

170 This study focused on European ancestry individuals. When larger cross-ancestry samples become
171 available, future studies should extend AD XWAS into these populations. Similarly, future, larger sex-
172 stratified AD XWAS may help identify sex-specific risk genes and genes escaping from XCI. Lastly, this study
173 did not provide conclusive insight into the causal gene at the *SLC9A7* locus, which future experimental
174 studies should interrogate.

175 **Conclusion**

176 We performed the first large-scale XWAS of AD and identified the novel *SLC9A7* risk locus. Overall, this
177 study significantly advances our knowledge of the genetics of AD and may provide novel biological drug
178 targets.

179 **Consent for publication**

180 Not applicable.

181 **Availability of data and materials**

182 Data used in the XWAS are available upon application to:

- 183 - dbGaP (<https://www.ncbi.nlm.nih.gov/gap/>)
- 184 - NIAGADS (<https://www.niagads.org/>)
- 185 - LONI (<https://ida.loni.usc.edu/>)
- 186 - AMP-AD knowledge portal / Synapse (<https://www.synapse.org/>)
- 187 - Rush (<https://www.radc.rush.edu/>)
- 188 - NACC (<https://naccdata.org/>)
- 189 - UKB (<https://www.ukbiobank.ac.uk/>)
- 190 - FinnGen (<https://www.finnngen.fi/en>)
- 191 - MVP (<https://www.mvp.va.gov/>)

192 The specific data repository and identifier for ADGC and ADSP data are indicated in **eTable1** of the
193 supplement.

194 The data, code, and phenotypes used to generate MVP results are accessible to researchers with MVP
195 data access. Due to VA policy, MVP is currently only accessible to VA researchers with a funded MVP
196 project, either through a VA Merit Award, career development award, or NIH R01. Additional information
197 is available at <https://genhub.va.gov/file/view/897656>. GWAS summary results for the MVP cohort will
198 be posted to dbGAP after publication.

199 Colocalization datasets are available from:

- 200 - AMP-AD knowledge portal / Synapse (<https://www.synapse.org/>; identifier: syn51150434)
- 201 - eQTL catalogue (<https://www.ebi.ac.uk/eqt1/>)
- 202 - GTEx (<https://www.gtexportal.org/home/>)

203 Summary statistics generated by this study will be deposited in both NIAGADS and the EMBL-EBI GWAS
204 Catalog.

205 **Competing/Conflicting interests**

206 The authors declare no competing or conflicting interests.

207 **Funding/Support**

208 Funding for this study was provided by the NIH (R00AG075238, M.E.B; AG060747 and AG047366, M.D.G)
209 and the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-
210 Curie (grant agreement No. 890650, Y.L.G.). JH was supported by grants from the NIH (NS108115), the
211 Alzheimer's Association (ABA-22-970304) and the Kleberg Foundation. This study included data from the
212 Million Veteran Program, Office of Research and Development, Veterans Health Administration. MVP data
213 analyses were supported by VA BLR&D grants BX004192 (MVP015; PI Logue) and BX005749 (MVP040; PI
214 Logue). Dr. Richard Hauger was supported by MVP022 award CX001727, VISN-22 VA Center of Excellence
215 for Stress and Mental Health (CESAMH), and National Institute of Aging R01 grants AG050595.

216 **Role of Funder/Sponsor**

217 The funding organizations and sponsors had no role in the design and conduct of the study; collection,
218 management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript;
219 and decision to submit the manuscript for publication.

220 **Authors' contributions**

221 M.E.B., Y.L. and M.D.G. had full access to all the data in the study and take responsibility for the integrity
222 of the data and the accuracy of the data analysis. M.E.B. performed data acquisition and analyses,
223 designed analyses, designed study, wrote paper, and obtained funding. Y.L. performed data acquisition
224 and analyses, designed analyses, designed study, and wrote paper. I.S. performed data acquisition and
225 analyses. J.H. co-wrote the paper. M.W.L. and J.M.G were involved in data, funding, and resource
226 acquisition. M.W.L, R.S., V.M., M.S.P., and R.L.H. were involved in conceptualization and study design. R.Z
227 and R.S. analyzed and curated data. V.N. performed data acquisition and analyses, designed study,
228 designed analyses, supervised analyses, and supervised work. M.D.G designed study, designed analyses,
229 supervised analyses, supervised work, wrote paper, and obtained funding. All authors contributed to
230 critical revision of the manuscript.

231 **Acknowledgements**

232 Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's
233 Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the
234 National Institute on Aging. The contents of this article do not represent the views of the National
235 Institutes of Health, the U.S. Department of Veterans Affairs, or the United States Government.

236 **Acknowledgments for the use of ADSP WES and WGS data**

237 The Alzheimer's Disease Sequencing Project (ADSP) is comprised of two Alzheimer's Disease (AD) genetics
238 consortia and three National Human Genome Research Institute (NHGRI) funded Large Scale Sequencing
239 and Analysis Centers (LSAC). The two AD genetics consortia are the Alzheimer's Disease Genetics
240 Consortium (ADGC) funded by NIA (U01 AG032984), and the Cohorts for Heart and Aging Research in
241 Genomic Epidemiology (CHARGE) funded by NIA (R01 AG033193), the National Heart, Lung, and Blood
242 Institute (NHLBI), other National Institute of Health (NIH) institutes and other foreign governmental and
243 non-governmental organizations. The Discovery Phase analysis of sequence data is supported through
244 UF1AG047133 (to Drs. Schellenberg, Farrer, Pericak-Vance, Mayeux, and Haines); U01AG049505 to Dr.
245 Seshadri; U01AG049506 to Dr. Boerwinkle; U01AG049507 to Dr. Wijsman; and U01AG049508 to Dr. Goate
246 and the Discovery Extension Phase analysis is supported through U01AG052411 to Dr. Goate,
247 U01AG052410 to Dr. Pericak-Vance and U01 AG052409 to Drs. Seshadri and Fornage.

248 Sequencing for the Follow Up Study (FUS) is supported through U01AG057659 (to Drs. PericakVance,
249 Mayeux, and Vardarajan) and U01AG062943 (to Drs. Pericak-Vance and Mayeux). Data generation and
250 harmonization in the Follow-up Phase is supported by U54AG052427 (to Drs. Schellenberg and Wang).
251 The FUS Phase analysis of sequence data is supported through U01AG058589 (to Drs. Destefano,
252 Boerwinkle, De Jager, Fornage, Seshadri, and Wijisman), U01AG058654 (to Drs. Haines, Bush, Farrer,
253 Martin, and Pericak-Vance), U01AG058635 (to Dr. Goate), RF1AG058066 (to Drs. Haines, Pericak-Vance,
254 and Scott), RF1AG057519 (to Drs. Farrer and Jun), R01AG048927 (to Dr. Farrer), and RF1AG054074 (to
255 Drs. Pericak-Vance and Beecham).

256 The ADGC cohorts include: Adult Changes in Thought (ACT) (U01 AG006781, U01 HG004610, U01
257 HG006375, U01 HG008657), the Alzheimer's Disease Centers (ADC) (P30 AG019610, P30 AG013846, P50
258 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50
259 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50
260 AG047366, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30
261 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50
262 AG005136, P50 AG033514, P50 AG005681, and P50 AG047270), the Chicago Health and Aging Project
263 (CHAP) (R01 AG11101, RC4 AG039085, K23 AG030944), Indianapolis Ibadan (R01 AG009956, P30
264 AG010133), the Memory and Aging Project (MAP) (R01 AG17917), Mayo Clinic (MAYO) (R01 AG032990,
265 U01 AG046139, R01 NS080820, RF1 AG051504, P50 AG016574), Mayo Parkinson's Disease controls
266 (NS039764, NS071674, 5RC2HG005605), University of Miami (R01 AG027944, R01 AG028786, R01
267 AG019085, IIRG09133827, A2011048), the Multi-Institutional Research in Alzheimer's Genetic
268 Epidemiology Study (MIRAGE) (R01 AG09029, R01 AG025259), the National Cell Repository for
269 Alzheimer's Disease (NCRAD) (U24 AG21886), the National Institute on Aging Late Onset Alzheimer's
270 Disease Family Study (NIA- LOAD) (R01 AG041797), the Religious Orders Study (ROS) (P30 AG10161, R01
271 AG15819), the Texas Alzheimer's Research and Care Consortium (TARCC) (funded by the Darrell K Royal
272 Texas Alzheimer's Initiative), Vanderbilt University/Case Western Reserve University (VAN/CWRU) (R01
273 AG019757, R01 AG021547, R01 AG027944, R01 AG028786, P01 NS026630, and Alzheimer's Association),
274 the Washington Heights-Inwood Columbia Aging Project (WHICAP) (RF1 AG054023), the University of
275 Washington Families (VA Research Merit Grant, NIA: P50AG005136, R01AG041797, NINDS:
276 R01NS069719), the Columbia University HispanicEstudio Familiar de Influencia Genetica de Alzheimer
277 (EFIGA) (RF1 AG015473), the University of Toronto (UT) (funded by Wellcome Trust, Medical Research
278 Council, Canadian Institutes of Health Research), and Genetic Differences (GD) (R01 AG007584). The
279 CHARGE cohorts are supported in part by National Heart, Lung, and Blood Institute (NHLBI) infrastructure

280 grant HL105756 (Psaty), RC2HL102419 (Boerwinkle) and the neurology working group is supported by the
281 National Institute on Aging (NIA) R01 grant AG033193.

282 The CHARGE cohorts participating in the ADSP include the following: Austrian Stroke Prevention Study
283 (ASPS), ASPS-Family study, and the Prospective Dementia Registry-Austria (ASPS/PRODEM-Aus), the
284 Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Erasmus
285 Rucphen Family Study (ERF), the Framingham Heart Study (FHS), and the Rotterdam Study (RS). ASPS is
286 funded by the Austrian Science Fond (FWF) grant number P20545-P05 and P13180 and the Medical
287 University of Graz. The ASPS-Fam is funded by the Austrian Science Fund (FWF) project I904),the EU Joint
288 Programme - Neurodegenerative Disease Research (JPND) in frame of the BRIDGET project (Austria,
289 Ministry of Science) and the Medical University of Graz and the Steiermärkische Krankenanstalten
290 Gesellschaft. PRODEM-Austria is supported by the Austrian Research Promotion agency (FFG) (Project No.
291 827462) and by the Austrian National Bank (Anniversary Fund, project 15435. ARIC research is carried out
292 as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C,
293 HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
294 HHSN268201100011C, and HHSN268201100012C). Neurocognitive data in ARIC is collected by U01
295 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI,
296 NINDS, NIA and NIDCD), and with previous brain MRI examinations funded by R01-HL70825 from the
297 NHLBI. CHS research was supported by contracts HHSN268201200036C, HHSN268200800007C,
298 N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and
299 grants U01HL080295 and U01HL130114 from the NHLBI with additional contribution from the National
300 Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629,
301 R01AG15928, and R01AG20098 from the NIA. FHS research is supported by NHLBI contracts N01-HC-
302 25195 and HHSN268201500001I. This study was also supported by additional grants from the NIA (R01s
303 AG054076, AG049607 and AG033040 and NINDS (R01 NS017950). The ERF study as a part of EUROSPAN
304 (European Special Populations Research Network) was supported by European Commission FP6 STRP
305 grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's
306 Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4- 2007-201413 by the
307 European Commission under the programme "Quality of Life and Management of the Living Resources"
308 of 5th Framework Programme (no. QLG2-CT-2002- 01254). High-throughput analysis of the ERF data was
309 supported by a joint grant from the Netherlands Organization for Scientific Research and the Russian
310 Foundation for Basic Research (NWO-RFBR 047.017.043). The Rotterdam Study is funded by Erasmus
311 Medical Center and Erasmus University, Rotterdam, the Netherlands Organization for Health Research

312 and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of
313 Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission
314 (DG XII), and the municipality of Rotterdam. Genetic data sets are also supported by the Netherlands
315 Organization of Scientific Research NWO Investments (175.010.2005.011, 911-03-012), the Genetic
316 Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in
317 the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organization
318 for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project 050-060-810.
319 All studies are grateful to their participants, faculty and staff. The content of these manuscripts is solely
320 the responsibility of the authors and does not necessarily represent the official views of the National
321 Institutes of Health or the U.S. Department of Health and Human Services.

322 The FUS cohorts include: the Alzheimer's Disease Centers (ADC) (P30 AG019610, P30 AG013846, P50
323 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50
324 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50
325 AG047366, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30
326 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50
327 AG005136, P50 AG033514, P50 AG005681, and P50 AG047270), Alzheimer's Disease Neuroimaging
328 Initiative (ADNI) (U19AG024904), Amish Protective Variant Study (RF1AG058066), Cache County Study
329 (R01AG11380, R01AG031272, R01AG21136, RF1AG054052), Case Western Reserve University Brain Bank
330 (CWRUBB) (P50AG008012), Case Western Reserve University Rapid Decline (CWRURD) (RF1AG058267,
331 NU38CK000480), CubanAmerican Alzheimer's Disease Initiative (CuAADI) (3U01AG052410), Estudio
332 Familiar de Influenza Genetica en Alzheimer (EFIGA) (5R37AG015473, RF1AG015473, R56AG051876),
333 Genetic and Environmental Risk Factors for Alzheimer Disease Among African Americans Study
334 (GenerAAtions) (2R01AG09029, R01AG025259, 2R01AG048927), Gwangju Alzheimer and Related
335 Dementias Study (GARD) (U01AG062602), Hussman Institute for Human Genomics Brain Bank (HIHGBB)
336 (R01AG027944, Alzheimer's Association "Identification of Rare Variants in Alzheimer Disease"), Ibadan
337 Study of Aging (IBADAN) (5R01AG009956), Mexican Health and Aging Study (MHAS) (R01AG018016),
338 Multi-Institutional Research in Alzheimer's Genetic Epidemiology (MIRAGE) (2R01AG09029,
339 R01AG025259, 2R01AG048927), Northern Manhattan Study (NOMAS) (R01NS29993), Peru Alzheimer's
340 Disease Initiative (PeADI) (RF1AG054074), Puerto Rican 1066 (PR1066) (Wellcome Trust
341 (GR066133/GR080002), European Research Council (340755)), Puerto Rican Alzheimer Disease Initiative
342 (PRADI) (RF1AG054074), Reasons for Geographic and Racial Differences in Stroke (REGARDS)
343 (U01NS041588), Research in African American Alzheimer Disease Initiative (REAAADI) (U01AG052410),

344 Rush Alzheimer's Disease Center (ROSMAP) (P30AG10161, R01AG15819, R01AG17919), University of
345 Miami Brain Endowment Bank (MBB), and University of Miami/Case Western/North Carolina A&T African
346 American (UM/CASE/NCAT) (U01AG052410, R01AG028786).

347 The four LSACs are: the Human Genome Sequencing Center at the Baylor College of Medicine (U54
348 HG003273), the Broad Institute Genome Center (U54HG003067), The American Genome Center at the
349 Uniformed Services University of the Health Sciences (U01AG057659), and the Washington University
350 Genome Institute (U54HG003079).

351 Biological samples and associated phenotypic data used in primary data analyses were stored at Study
352 Investigators institutions, and at the National Cell Repository for Alzheimer's Disease (NCRAD,
353 U24AG021886) at Indiana University funded by NIA. Associated Phenotypic Data used in primary and
354 secondary data analyses were provided by Study Investigators, the NIA funded Alzheimer's Disease
355 Centers (ADCs), and the National Alzheimer's Coordinating Center (NACC, U01AG016976) and the
356 National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS, U24AG041689)
357 at the University of Pennsylvania, funded by NIA This research was supported in part by the Intramural
358 Research Program of the National Institutes of health, National Library of Medicine. Contributors to the
359 Genetic Analysis Data included Study Investigators on projects that were individually funded by NIA, and
360 other NIH institutes, and by private U.S. organizations, or foreign governmental or nongovernmental
361 organizations.

362 An up to date acknowledgment statement can be found on the ADSP
363 site: <https://www.niagads.org/adsp/content/acknowledgement-statement>.

364 Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative
365 (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award
366 number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of
367 Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie,
368 Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen;
369 Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and
370 Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio;
371 GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson &
372 Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso
373 Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals

374 Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition
375 Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites
376 in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of
377 Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and
378 Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the
379 University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the
380 University of Southern California.

381 Additional information to include in an acknowledgment statement can be found on the LONI
382 site: https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Data_Use_Agreement.pdf.

383 The Alzheimer's Disease Genetics Consortium (ADGC) supported sample preparation, whole exome
384 sequencing and data processing through NIA grant U01AG032984. Sequencing data generation and
385 harmonization is supported by the Genome Center for Alzheimer's Disease, U54AG052427, and data
386 sharing is supported by NIAGADS, U24AG041689. Samples from the National Centralized Repository for
387 Alzheimer's Disease and Related Dementias (NCRAD), which receives government support under a
388 cooperative agreement grant (U24 AG021886) awarded by the National Institute on Aging (NIA), were
389 used in this study. We thank contributors who collected samples used in this study, as well as patients
390 and their families, whose help and participation made this work possible. NIH grants supported
391 enrollment and data collection for the individual studies including: GenerAAtions R01AG20688 (PI M.
392 Daniele Fallin, PhD); Miami/Duke R01 AG027944, R01 AG028786 (PI Margaret A. Pericak-Vance, PhD); NC
393 A&T P20 MD000546, R01 AG28786-01A1 (PI Goldie S. Byrd, PhD); Case Western (PI Jonathan L. Haines,
394 PhD); MIRAGE R01 AG009029 (PI Lindsay A. Farrer, PhD); ROS P30AG10161, R01AG15819, R01AG30146,
395 TGen (PI David A. Bennett, MD); MAP R01AG17917, R01AG15819, TGen (PI David A. Bennett, MD). The
396 NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded
397 ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG062428-01 (PI
398 James Leverenz, MD) P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50
399 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn
400 Albert, PhD), P30 AG062421-01 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald Petersen, MD,
401 PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI
402 Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50
403 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI
404 Frank LaFerla, PhD), P30 AG062429-01 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD),
405 P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI

406 Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez,
407 MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI
408 Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI Sanjay Asthana,
409 MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD).

410 This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991,
411 RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and
412 clinical characterization of research participants at Washington University were supported by NIH P50
413 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made
414 possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry
415 at Washington University School of Medicine.

416 We thank the contributors who collected samples used in this study, as well as patients and their families,
417 whose help and participation made this work possible. Members of the National Institute on Aging Late-
418 Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD NCRAD) Family Study
419 Group include the following: Richard Mayeux, MD, MSc; Martin Farlow, MD; Tatiana Foroud, PhD; Kelley
420 Faber, MS; Bradley F. Boeve, MD; Neill R. Graff-Radford, MD; David A. Bennett, MD; Robert A. Sweet, MD;
421 Roger Rosenberg, MD; Thomas D. Bird, MD; Carlos Cruchaga, PhD; and Jeremy M. Silverman, PhD.

422 This work was partially supported by grant funding from NIH R01 AG039700 and NIH P50 AG005136.
423 Subjects and samples used here were originally collected with grant funding from NIH U24 AG026395,
424 U24 AG021886, P50 AG008702, P01 AG007232, R37 AG015473, P30 AG028377, P50 AG05128, P50
425 AG16574, P30 AG010133, P50 AG005681, P01 AG003991, U01MH046281, U01 MH046290 and U01
426 MH046373. The funders had no role in study design, analysis or preparation of the manuscript. The
427 authors declare no competing interests.

428 This work was supported by the National Institutes of Health (R01 AG027944, R01 AG028786 to MAPV,
429 R01 AG019085 to JLH, P20 MD000546); a joint grant from the Alzheimer's Association (SG-14-312644)
430 and the Fidelity Biosciences Research Initiative to MAPV; the BrightFocus Foundation (A2011048 to
431 MAPV). NIA-LOAD Family-Based Study supported the collection of samples used in this study through NIH
432 grants U24 AG026395 and R01 AG041797 and the MIRAGE cohort was supported through the NIH grants
433 R01 AG025259 and R01 AG048927. We thank contributors, including the Alzheimer's disease Centers who
434 collected samples used in this study, as well as patients and their families, whose help and participation
435 made this work possible. Study design: HNC, BWK, JLH, MAPV; Sample collection: MLC, JMV, RMC, LAF,
436 JLH, MAPV; Whole exome sequencing and Sanger sequencing: SR, PLW; Sequencing data analysis: HNC,

437 BWK, KLHN, SR, MAK, JRG, ERM, GWB, MAPV; Statistical analysis: BWK, KLHN, JMJ, MAPV; Preparation of
438 manuscript: HNC, BWK. The authors jointly discussed the experimental results throughout the duration
439 of the study. All authors read and approved the final manuscript.

440 Data collection and sharing for this project was supported by the Washington Heights-Inwood Columbia
441 Aging Project (WHICAP, PO1AG07232, R01AG037212, RF1AG054023) funded by the National Institute on
442 Aging (NIA) and by the National Center for Advancing Translational Sciences, National Institutes of Health,
443 through Grant Number UL1TR001873. This manuscript has been reviewed by WHICAP investigators for
444 scientific content and consistency of data interpretation with previous WHICAP Study publications. We
445 acknowledge the WHICAP study participants and the WHICAP research and support staff for their
446 contributions to this study.

447 This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991,
448 RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and
449 clinical characterization of research participants at Washington University were supported by NIH P50
450 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made
451 possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry
452 at Washington University School of Medicine.

453 We thank the contributors who collected samples used in this study, as well as patients and their families,
454 whose help and participation made this work possible. Members of the National Institute on Aging Late-
455 Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD NCRAD) Family Study
456 Group include the following: Richard Mayeux, MD, MSc; Martin Farlow, MD; Tatiana Foroud, PhD; Kelley
457 Faber, MS; Bradley F. Boeve, MD; Neill R. Graff-Radford, MD; David A. Bennett, MD; Robert A. Sweet, MD;
458 Roger Rosenberg, MD; Thomas D. Bird, MD; Carlos Cruchaga, PhD; and Jeremy M. Silverman, PhD.

459 This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991,
460 RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and
461 clinical characterization of research participants at Washington University were supported by NIH P50
462 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made
463 possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry
464 at Washington University School of Medicine.

465 We thank the contributors who collected samples used in this study, as well as patients and their families,
466 whose help and participation made this work possible. Members of the National Institute on Aging Late-

467 Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD NCRAD) Family Study
468 Group include the following: Richard Mayeux, MD, MSc; Martin Farlow, MD; Tatiana Foroud, PhD; Kelley
469 Faber, MS; Bradley F. Boeve, MD; Neill R. Graff-Radford, MD; David A. Bennett, MD; Robert A. Sweet, MD;
470 Roger Rosenberg, MD; Thomas D. Bird, MD; Carlos Cruchaga, PhD; and Jeremy M. Silverman, PhD.

471 Mayo RNAseq Study- Study data were provided by the following sources: The Mayo Clinic Alzheimer's
472 Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic,
473 Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer's Disease
474 Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA
475 grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786,
476 R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and
477 support from Mayo Foundation. Study data includes samples collected through the Sun Health Research
478 Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is
479 supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain
480 and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30
481 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract
482 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts
483 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox
484 Foundation for Parkinson's Research

485 ROSMAP- We are grateful to the participants in the Religious Order Study, the Memory and Aging Project.
486 This work is supported by the US National Institutes of Health [U01 AG046152, R01 AG043617, R01
487 AG042210, R01 AG036042, R01 AG036836, R01 AG032990, R01 AG18023, RC2 AG036547, P50 AG016574,
488 U01 ES017155, KL2 RR024151, K25 AG041906-01, R01 AG30146, P30 AG10161, R01 AG17917, R01
489 AG15819, K08 AG034290, P30 AG10161 and R01 AG11101.

490 Mount Sinai Brain Bank (MSBB)- This work was supported by the grants R01AG046170, RF1AG054014,
491 RF1AG057440 and R01AG057907 from the NIH/National Institute on Aging (NIA). R01AG046170 is a
492 component of the AMP-AD Target Discovery and Preclinical Validation Project. Brain tissue collection and
493 characterization was supported by NIH HHSN271201300031C.

494 This study was supported by the National Institute on Aging (NIA) grants AG030653, AG041718, AG064877
495 and P30-AG066468.

496 We would like to thank study participants, their families, and the sample collectors for their invaluable
497 contributions. This research was supported in part by the National Institute on Aging grant U01AG049508
498 (PI Alison M. Goate). This research was supported in part by Genentech, Inc. (PI Alison M. Goate, Robert
499 R. Graham).

500 The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by these NIA-
501 funded ADCs: P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI
502 Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD),
503 P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P30
504 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David
505 Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50
506 AG005131 (PI Douglas Galasko, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John
507 Trojanowski, MD, PhD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD),
508 P50 AG005136 (PI Thomas Grabowski, MD), P50 AG005681 (PI John Morris, MD), P30 AG028377 (Kathleen
509 Welsh-Bohmer, PhD), and P50 AG008671 (PI Henry Paulson, MD, PhD).

510 Samples from the National Cell Repository for Alzheimer's Disease (NCRAD), which receives government
511 support under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging
512 (NIA), were used in this study. We thank contributors who collected samples used in this study, as well as
513 patients and their families, whose help and participation made this work possible.

514 The Alzheimer's Disease Genetics Consortium supported the collection of samples used in this study
515 through National Institute on Aging (NIA) grants U01AG032984 and RC2AG036528.

516 We acknowledge the generous contributions of the Cache County Memory Study participants. Sequencing
517 for this study was funded by RF1AG054052 (PI: John S.K. Kauwe)

518 **Acknowledgments for the use of GWAS data distributed by NIAGADS**

519 The NIA Genetics of Alzheimer's Disease Data Storage Site (NIAGADS) is supported by a collaborative
520 agreement from the National Institute on Aging, U24AG041689.

521 NG00047: The NIA supported this work through grants U01-AG032984, RC2-AG036528, U01-AG016976
522 (Dr Kukull); U24 AG026395, U24 AG026390, R01AG037212, R37 AG015473 (Dr Mayeux); K23AG034550
523 (Dr Reitz); U24-AG021886 (Dr Foroud); R01AG009956, RC2 AG036650 (Dr Hall); UO1 AG06781, UO1
524 HG004610 (Dr Larson); R01 AG009029 (Dr Farrer); 5R01AG20688 (Dr Fallin); P50 AG005133, AG030653

525 (Dr Kamboh); R01 AG019085 (Dr Haines); R01 AG1101, R01 AG030146, RC2 AG036650 (Dr Evans);
526 P30AG10161, R01AG15819, R01AG30146, R01AG17917, R01AG15819 (Dr Bennett); R01AG028786 (Dr
527 Manly); R01AG22018, P30AG10161 (Dr Barnes); P50AG16574 (Dr Ertekin-Taner, Dr Graff-Radford), R01
528 AG032990 (Dr Ertekin-Taner), KL2 RR024151 (Dr Ertekin-Taner); R01 AG027944, R01 AG028786 (Dr
529 Pericak-Vance); P20 MD000546, R01 AG28786-01A1 (Dr Byrd); AG005138 (Dr Buxbaum); P50 AG05681,
530 P01 AG03991, P01 AG026276 (Dr Goate); and P30AG019610, P30AG13846, U01-AG10483, R01CA129769,
531 R01MH080295, R01AG017173, R01AG025259, R01AG33193, P50AG008702, P30AG028377, AG05128,
532 AG025688, P30AG10133, P50AG005146, P50AG005134, P01AG002219, P30AG08051, MO1RR00096,
533 UL1RR029893, P30AG013854, P30AG008017, R01AG026916, R01AG019085, P50AG016582,
534 UL1RR02777, R01AG031581, P30AG010129, P50AG016573, P50AG016575, P50AG016576,
535 P50AG016577, P50AG016570, P50AG005131, P50AG023501, P50AG019724, P30AG028383,
536 P50AG008671, P30AG010124, P50AG005142, P30AG012300, AG010491, AG027944, AG021547,
537 AG019757, P50AG005136 (Alzheimer Disease Genetics Consortium [ADGC]). We thank Creighton Phelps,
538 Stephen Synder, and Marilyn Miller from the NIA, who are ex-officio members of the ADGC. Support was
539 also provided by the Alzheimer's Association (IIRG-08-89720 [Dr Farrer] and IIRG-05-14147 [Dr Pericak-
540 Vance]), National Institute of Neurological Disorders and Stroke grant NS39764, National Institute of
541 Mental Health grant MH60451, GlaxoSmithKline, and the Office of Research and Development,
542 Biomedical Laboratory Research Program, US Department of Veterans Affairs Administration. For the
543 ADGC, biological samples and associated phenotypic data used in primary data analyses were stored at
544 principal investigators' institutions and at the National Cell Repository for Alzheimer's Disease (NCRAD) at
545 Indiana University, funded by the NIA. Associated phenotypic data used in secondary data analyses were
546 stored at the National Alzheimer's Coordinating Center and at the NIA Alzheimer's Disease Data Storage
547 Site at the University of Pennsylvania, funded by the NIA. Contributors to the genetic analysis data
548 included principal investigators on projects individually funded by the NIA, other NIH institutes, or private
549 entities.

550 **Acknowledgments for other GWAS and phenotype data**

551 **NACC**

552 The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-
553 funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG062428-
554 01 (PI James Leverenz, MD) P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD),
555 P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI

556 Marilyn Albert, PhD), P30 AG062421-01 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald
557 Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30
558 AG013854 (PI Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett,
559 MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50
560 AG016573 (PI Frank LaFerla, PhD), P30 AG062429-01(PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce
561 Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30
562 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133
563 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30
564 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI
565 Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter,
566 MD, PhD).

567 **MARS & LATC**

568 We thank all Minority Aging Research Study and Latino Core participants and the Rush Alzheimer’s Disease
569 Center staff. This database was funded by the NIH/NIA grants R01AG22018 (MARS) and P30AG 072975
570 (ADC).

571 **GenADA**

572 The genotypic and associated phenotypic data used in the study “Multi-Site Collaborative Study for
573 Genotype-Phenotype Associations in Alzheimer’s Disease (GenADA)” were provided by the
574 GlaxoSmithKline, R&D Limited.

575 **ROSMAP**

576 ROSMAP study data were provided by the Rush Alzheimer’s Disease Center, Rush University Medical
577 Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161, R01AG15819,
578 R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public
579 Health, and the Translational Genomics Research Institute.

580 **AddNeuroMed**

581 The AddNeuroMed data are from a public-private partnership supported by EFPIA companies and SMEs
582 as part of InnoMed (Innovative Medicines in Europe), an Integrated Project funded by the European Union
583 of the Sixth Framework program priority FP6-2004-LIFESCIHEALTH-5. Clinical leads responsible for data
584 collection are Iwona Kłoszewska (Lodz), Simon Lovestone (London), Patrizia Mecocci (Perugia), Hilikka
585 Soinenen (Kuopio), Magda Tsolaki (Thessaloniki), and Bruno Vellas (Toulouse), imaging leads are Andy

586 Simmons (London), Lars-Olad Wahlund (Stockholm) and Christian Spenger (Zurich) and bioinformatics
587 leads are Richard Dobson (London) and Stephen Newhouse (London).

588 **ADNI**

589 Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative
590 (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award
591 number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of
592 Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie.
593 Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica. Inc.; Biogen;
594 Bristol-Myers Squibb Company; CereSpir. Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals. Inc.; Eli Lilly and
595 Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech. Inc.; Fujirebio;
596 GE HealthControlsare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development. LLC.;
597 Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co. Inc.;
598 Meso Scale Diagnostics. LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals
599 Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition
600 Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites
601 in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of
602 Health. The grantee organization is the Northern California Institute for Research and Education, and the
603 study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern
604 California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern
605 California.

606 **NCRAD**

607 Biological samples used in this study were stored at study investigators' institutions and at the National
608 Cell Repository for Alzheimer's Disease (NCRAD) at Indiana University, which receives government support
609 under a cooperative agreement grant (U24 AG21886) awarded by the National Institute on Aging (NIA).
610 We thank contributors who collected samples used in this study, as well as patients and their families,
611 whose help and participation made this work possible.

612 **UK Biobank**

613 UK Biobank data were analyzed under Application Number 45420.

614

615 **VA Million Veteran Program: Core Acknowledgement**

616 **MVP Program Office**

- 617 - Sumitra Muralidhar, Ph.D., Program Director
618 US Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420
619 - Jennifer Moser, Ph.D., Associate Director, Scientific Programs
620 US Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420
621 - Jennifer E. Deen, B.S., Associate Director, Cohort & Public Relations
622 US Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420

623 **MVP Executive Committee**

- 624 - Co-Chair: Philip S. Tsao, Ph.D.
625 VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304
626 - Co-Chair: Sumitra Muralidhar, Ph.D.
627 US Department of Veterans Affairs, 810 Vermont Avenue NW, Washington, DC 20420
628 - J. Michael Gaziano, M.D., M.P.H.
629 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
630 - Elizabeth Hauser, Ph.D.
631 Durham VA Medical Center, 508 Fulton Street, Durham, NC 27705
632 - Amy Kilbourne, Ph.D., M.P.H.
633 VA HSR&D, 2215 Fuller Road, Ann Arbor, MI 48105
634 - Michael Matheny, M.D., M.S., M.P.H.
635 VA Tennessee Valley Healthcare System, 1310 24th Ave. South, Nashville, TN 37212
636 - Dave Oslin, M.D.
637 Philadelphia VA Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104

638 **MVP Co-Principal Investigators**

- 639 - J. Michael Gaziano, M.D., M.P.H.
640 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
641 - Philip S. Tsao, Ph.D.
642 VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304

643 **MVP Core Operations**

- 644 - Jessica V. Brewer, M.P.H., Director, Cohort Operations
645 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
646 - Mary T. Brophy M.D., M.P.H., Director, Biorepository
647 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
648 - Kelly Cho, M.P.H, Ph.D., Director, MVP Phenomics
649 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
650 - Lori Churby, B.S., Director, Regulatory Affairs
651 VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304
652 - Scott L. DuVall, Ph.D., Director, VA Informatics and Computing Infrastructure (VINCI)
653 VA Salt Lake City Health Care System, 500 Foothill Drive, Salt Lake City, UT 84148
654 - Saiju Pyarajan Ph.D., Director, Data and Computational Sciences

- 655 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
656 - Luis E. Selva, Ph.D., Director, MVP Biorepository Coordination
657 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
658 - Shahpoor (Alex) Shayan, M.S., Director, MVP PRE Informatics
659 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
660 - Stacey B. Whitbourne, Ph.D., Director, MVP Cohort Development and Management
661 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
662 - MVP Coordinating Centers
663 o MVP Coordinating Center, Boston - J. Michael Gaziano, M.D., M.P.H.
664 VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130
665 o MVP Coordinating Center, Palo Alto – Philip S. Tsao, Ph.D.
666 VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304
667 o MVP Information Center, Canandaigua – Brady Stephens, M.S.
668 Canandaigua VA Medical Center, 400 Fort Hill Avenue, Canandaigua, NY 14424
669 o Cooperative Studies Program Clinical Research Pharmacy Coordinating Center,
670 Albuquerque – Todd Connor, Pharm.D.; Dean P. Argyres, B.S., M.S.
671 New Mexico VA Health Care System, 1501 San Pedro Drive SE, Albuquerque, NM 87108

672 MVP Publications and Presentations Committee

- 673 - Co-Chair: Themistocles L. Assimes, M.D., Ph. D
674 VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA 94304
675 - Co-Chair: Adriana Hung, M.D.; M.P.H
676 VA Tennessee Valley Healthcare System, 1310 24th Ave. South, Nashville, TN 37212
677 - Co-Chair: Henry Kranzler, M.D.
678 Philadelphia VA Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104

679 MVP Local Site Investigators

- 680 - Samuel Aguayo, M.D., Phoenix VA Health Care System
681 650 E. Indian School Road, Phoenix, AZ 85012
682 - Sunil Ahuja, M.D., South Texas Veterans Health Care System
683 7400 Merton Minter Boulevard, San Antonio, TX 78229
684 - Kathrina Alexander, M.D., Veterans Health Care System of the Ozarks
685 1100 North College Avenue, Fayetteville, AR 72703
686 - Xiao M. Androulakis, M.D., Columbia VA Health Care System
687 6439 Garners Ferry Road, Columbia, SC 29209
688 - Prakash Balasubramanian, M.D., William S. Middleton Memorial Veterans Hospital
689 2500 Overlook Terrace, Madison, WI 53705
690 - Zuhair Ballas, M.D., Iowa City VA Health Care System
691 601 Highway 6 West, Iowa City, IA 52246-2208
692 - Elizabeth S. Bast, M.D., M.P.H., Miami VA Health Care System
693 1201 NW 16th Street, 11 GRC, Miami FL 33125
694 - Jean Beckham, Ph.D., Durham VA Medical Center
695 508 Fulton Street, Durham, NC 27705
696 - Sujata Bhushan, M.D., VA North Texas Health Care System
697 4500 S. Lancaster Road, Dallas, TX 75216
698 - Edward Boyko, M.D., VA Puget Sound Health Care System

699 1660 S. Columbian Way, Seattle, WA 98108-1597
700 - David Cohen, M.D., Portland VA Medical Center
701 3710 SW U.S. Veterans Hospital Road, Portland, OR 97239
702 - Louis Dellitalia, M.D., Birmingham VA Medical Center
703 700 S. 19th Street, Birmingham AL 35233
704 - Gerald Wayne Dryden, Jr., M.D., Ph.D., Louisville VA Medical Center
705 800 Zorn Avenue, Louisville, KY 40206
706 - L. Christine Faulk, M.D., Robert J. Dole VA Medical Center
707 5500 East Kellogg Drive, Wichita, KS 67218-1607
708 - Joseph Fayad, M.D., VA Southern Nevada Healthcare System
709 6900 North Pecos Road, North Las Vegas, NV 89086
710 - Daryl Fujii, Ph.D., VA Pacific Islands Health Care System
711 459 Patterson Rd, Honolulu, HI 96819
712 - Saib Gappy, M.D., John D. Dingell VA Medical Center
713 4646 John R Street, Detroit, MI 48201
714 - Frank Gesek, Ph.D., White River Junction VA Medical Center
715 163 Veterans Drive, White River Junction, VT 05009
716 - Michael Godschalk, M.D., Richmond VA Medical Center
717 1201 Broad Rock Blvd., Richmond, VA 23249
718 - Jennifer Greco, M.D., Sioux Falls VA Health Care System
719 2501 W 22nd Street, Sioux Falls, SD 57105
720 - Todd W. Gress, M.D., Ph.D., Hershel “Woody” Williams VA Medical Center
721 1540 Spring Valley Drive, Huntington, WV 25704
722 - Samir Gupta, M.D., M.S.C.S., VA San Diego Healthcare System
723 3350 La Jolla Village Drive, San Diego, CA 92161
724 - Salvador Gutierrez, M.D., Edward Hines, Jr. VA Medical Center
725 5000 South 5th Avenue, Hines, IL 60141
726 - Mark Hamner, M.D., Ralph H. Johnson VA Medical Center
727 109 Bee Street, Mental Health Research, Charleston, SC 29401
728 - John Harley, M.D., Ph.D., Cincinnati VA Medical Center
729 3200 Vine Street, Cincinnati, OH 45220
730 - Daniel J. Hogan, M.D., Bay Pines VA Healthcare System
731 10,000 Bay Pines Blvd Bay Pines, FL 33744
732 - Adriana Hung, M.D., M.P.H., VA Tennessee Valley Healthcare System
733 1310 24th Avenue, South Nashville, TN 37212
734 - Robin Hurley, M.D., W.G. (Bill) Hefner VA Medical Center
735 1601 Brenner Ave, Salisbury, NC 28144
736 - Pran Iruvanti, D.O., Ph.D., Hampton VA Medical Center
737 100 Emancipation Drive, Hampton, VA 23667
738 - Frank Jacono, M.D., VA Northeast Ohio Healthcare System
739 10701 East Boulevard, Cleveland, OH 44106
740 - Darshana Jhala, M.D., Philadelphia VA Medical Center
741 3900 Woodland Avenue, Philadelphia, PA 19104
742 - Seema Joshi, M.D., F.A.C.P., ABOIM; VA Eastern Kansas Health Care System
743 4101 S 4th Street Trafficway, Leavenworth, KS 66048
744 - Scott Kinlay, M.B.B.S., Ph.D., VA Boston Healthcare System
745 150 S. Huntington Avenue, Boston, MA 02130
746 - Michael Landry, Ph.D., Southeast Louisiana Veterans Health Care System

747 2400 Canal Street, New Orleans, LA 70119
748 - Peter Liang, M.D., M.P.H., VA New York Harbor Healthcare System
749 423 East 23rd Street, New York, NY 10010
750 - Suthat Liangpunsakul, M.D., M.P.H., Richard Roudebush VA Medical Center
751 1481 West 10th Street, Indianapolis, IN 46202
752 - Jack Lichy, M.D., Ph.D., Washington DC VA Medical Center
753 50 Irving St, Washington, D. C. 20422
754 - Tze Shien Lo, M.D., Fargo VA Health Care System
755 2101 N. Elm, Fargo, ND 58102
756 - C. Scott Mahan, M.D., Charles George VA Medical Center
757 1100 Tunnel Road, Asheville, NC 28805
758 - Ronnie Marrache, M.D., VA Maine Healthcare System Center, Augusta, ME 04330
759 - Stephen Mastorides, M.D., James A. Haley Veterans' Hospital
760 13000 Bruce B. Downs Blvd, Tampa, FL 33612
761 - Kristin Mattocks, Ph.D., M.P.H., Central Western Massachusetts Healthcare System
762 421 North Main Street, Leeds, MA 01053
763 - Paul Meyer, M.D., Ph.D., Southern Arizona VA Health Care System
764 3601 S 6th Avenue, Tucson, AZ 85723
765 - Jonathan Moorman, M.D., Ph.D., James H. Quillen VA Medical Center
766 Corner of Lamont & Veterans Way, Mountain Home, TN 37684
767 - Providencia Morales, R.N., Northern Arizona VA Health Care System
768 500 Highway 89 North, Prescott, AZ 86313
769 - Timothy Morgan, M.D., VA Long Beach Healthcare System
770 5901 East 7th Street Long Beach, CA 90822
771 - Maureen Murdoch, M.D., M.P.H., Minneapolis VA Health Care System
772 One Veterans Drive, Minneapolis, MN 55417
773 - Eknath Naik, M.D., Ph.D., West Palm Beach VA Medical Center,
774 7305 North Military Trail, West Palm Beach, FL 33410-6400
775 - James Norton, Ph.D., VA Health Care Upstate New York
776 113 Holland Avenue, Albany, NY 12208
777 - Olaoluwa Okusaga, M.D., Michael E. DeBakey VA Medical Center
778 2002 Holcombe Blvd, Houston, TX 77030
779 - Michael K. Ong, M.D., VA Greater Los Angeles Health Care System
780 11301 Wilshire Blvd, Los Angeles, CA 90073
781 - Kris Ann Oursler, M.D., Salem VA Medical Center
782 1970 Roanoke Blvd, Salem, VA 24153
783 - Ismene Petrakis, M.D., VA Connecticut Healthcare System
784 950 Campbell Avenue, West Haven, CT 06516
785 - Samuel Poon, M.D., Manchester VA Medical Center
786 718 Smyth Road, Manchester, NH 03104
787 - Amneet S. Rai, Pharm.D., VA Sierra Nevada Health Care System
788 975 Kirman Avenue, Reno, NV 89502
789 - Michael Rauchman, M.D., St. Louis VA Health Care System
790 915 North Grand Blvd, St. Louis, MO 63106
791 - Richard Servatius, Ph.D., Syracuse VA Medical Center
792 800 Irving Avenue, Syracuse, NY 13210
793 - Satish Sharma, M.D., Providence VA Medical Center
794 830 Chalkstone Avenue, Providence, RI 02908


795 - River Smith, Ph.D., Eastern Oklahoma VA Health Care System
796 1011 Honor Heights Drive, Muskogee, OK 74401
797 - Peruvemba Sriram, M.D., N. FL/S. GA Veterans Health System
798 1601 SW Archer Road, Gainesville, FL 32608
799 - Patrick Stollo, Jr., M.D., VA Pittsburgh Health Care System
800 University Drive, Pittsburgh, PA 15240
801 - Neeraj Tandon, M.D., Overton Brooks VA Medical Center
802 510 East Stoner Ave, Shreveport, LA 71101
803 - Philip Tsao, Ph.D., VA Palo Alto Health Care System
804 3801 Miranda Avenue, Palo Alto, CA 94304-1290
805 - Gerardo Villareal, M.D., New Mexico VA Health Care System
806 1501 San Pedro Drive, S.E. Albuquerque, NM 87108
807 - Jessica Walsh, M.D., VA Salt Lake City Health Care System
808 500 Foothill Drive, Salt Lake City, UT 84148
809 - John Wells, Ph.D., Edith Nourse Rogers Memorial Veterans Hospital
810 200 Springs Road, Bedford, MA 01730
811 - Jeffrey Whittle, M.D., M.P.H., Clement J. Zablocki VA Medical Center
812 5000 West National Avenue, Milwaukee, WI 53295
813 - Mary Whooley, M.D., San Francisco VA Health Care System
814 4150 Clement Street, San Francisco, CA 94121
815 - Peter Wilson, M.D., Atlanta VA Medical Center
816 1670 Clairmont Road, Decatur, GA 30033
817 - Junzhe Xu, M.D., VA Western New York Healthcare System
818 3495 Bailey Avenue, Buffalo, NY 14215-1199
819 - Shing Shing Yeh, Ph.D., M.D., Northport VA Medical Center
820 79 Middleville Road, Northport, NY 11768
821 - Andrew W. Yen, M.D., VA Northern California Health Care System
822 10535 Hospital Way, Mather, CA 95655

823 References


- 824 1. Sun L, Wang Z, Lu T, Manolio TA, Paterson AD. eXclusionarY: 10 years later, where
825 are the sex chromosomes in GWASs? *The American Journal of Human Genetics*.
826 2023;110(6):903-912. doi:10.1016/j.ajhg.2023.04.009
- 827 2. Alzheimer's Association. Alzheimer's disease facts and figures. *Alzheimer's and*
828 *Dementia*. 2023;19(4):1598-1695. doi:10.1002/alz.13016
- 829 3. NIAGADS. NG00067 – ADSP Umbrella. Published 2021. Accessed November 1,
830 2021. <https://dss.niagads.org/datasets/ng00067/>
- 831 4. Kuzma A, Valladares O, Cweibel R, et al. NIAGADS: The NIA Genetics of Alzheimer's
832 Disease Data Storage Site. *Alzheimer's & Dementia*. 2016;12(11):1200-1203.
833 doi:10.1016/j.jalz.2016.08.018
- 834 5. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep
835 phenotyping and genomic data. *Nature*. 2018;562:203-209. doi:10.1038/s41586-
836 018-0579-z
- 837 6. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-
838 phenotyped isolated population. *Nature*. 2023;613(7944):508-518.
839 doi:10.1038/S41586-022-05473-8
- 840 7. Sherva R, Zhang R, Sahelijo N, et al. African ancestry GWAS of dementia in a large
841 military cohort identifies significant risk loci. *Mol Psychiatry*. 2023;28(3):1293-
842 1302. doi:10.1038/s41380-022-01890-3
- 843 8. Hunter-Zinck H, Shi Y, Li M, et al. Genotyping Array Design and Data Quality
844 Control in the Million Veteran Program. *The American Journal of Human Genetics*.
845 2020;106(4):535-548. doi:10.1016/J.AJHG.2020.03.004
- 846 9. Le Guen Y, Napolioni V, Belloy ME, et al. Common X-Chromosome Variants Are
847 Associated with Parkinson Disease Risk. *Ann Neurol*. 2021;90(1):22-34.
848 doi:10.1002/ana.26051
- 849 10. Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new
850 loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet*.
851 2019;51(3):404-413. doi:10.1038/s41588-018-0311-9
- 852 11. Loh P ru, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for
853 biobank-scale datasets. *Nat Genet*. 2018;50:906-908. doi:10.1038/s41588-018-
854 0144-6

- 855
856
857
12. Sidorenko J, Kassam I, Kemper KE, et al. The effect of X-linked dosage compensation on complex trait variation. *Nat Commun.* 2019;10(1). doi:10.1038/s41467-019-10598-y
- 858
859
860
13. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *PLoS Genet.* 2014;10(5):1-15. doi:10.1371/journal.pgen.1004383
- 861
862
863
14. Andrews SJ, Renton AE, Fulton-Howard B, Podlesny-Drabiniok A, Marcora E, Goate AM. The complex genetic architecture of Alzheimer’s disease: novel insights and future directions. *EBioMedicine.* 2023;90. doi:10.1016/J.EBIOM.2023.104511
- 864
865
866
867
15. Stopschinski BE, Holmes BB, Miller GM, et al. Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau versus alfa-synuclein and beta-amyloid aggregates. *Journal of Biological Chemistry.* 2018;293(27):10826-10840. doi:10.1074/jbc.RA117.000378
- 868
869
870
16. Pohlkamp T, Xian X, Wong CH, et al. NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces Amyloid plaque load. *Elife.* 2021;10. doi:10.7554/eLife.72034
- 871
872
873

A



B



874

875 **Figure 1. X chromosome-wide association study of Alzheimer's disease. A)** Overview of study design and
 876 sample sizes. To increase specificity to AD (rather than ADD), the XWAS meta-analysis was intersected to
 877 variants with association results in ADGC (which used only clinically confirmed cases and controls). **B)**
 878 Manhattan plot for the XWAS meta-analysis. The dotted line indicates X-chromosome-wide significance
 879 ($P\text{-value} < 1e\text{-}5$) and full line indicates genome-wide significance ($P\text{-value} < 5e\text{-}8$). Lead variants for
 880 independent loci are annotated with their nearest protein-coding gene (Gencode v42).

881 **Table 1. X chromosome-wide association study of Alzheimer’s disease: Associated lead variants.** The Direction column indicates the association
882 effect direction across meta-analyzed cohorts following the order of ADGC, ADSP, UKB, FinnGen, MVP-1 (using health registry status), and MVP-2
883 (using proxy status). A question mark indicates the variant was not available in the respective cohort. Variants are annotated using dbSNP153.
884 Association signals passing genome-wide significance are bolded.

Lead variant	Nearest protein		BP	EA	OA	No. Subjects	EAF	OR [95%-CI] ‡	P	Direction
	coding gene	Consequence								
rs150798997	<i>NLGN4X</i>	intergenic	5,733,126	A	T	1,145,553	0.32%	0.644 [0.537, 0.772]	2.08E-06	- ? - - - -
rs12852495	<i>MID1</i>	intronic	10,458,864	T	C	1,151,353	0.26%	1.538 [1.276, 1.855]	6.60E-06	+ + + + + +
rs2142791	<i>SLC9A7</i>	intronic	46,691,127	C	A	1,152,185	46.12%	1.054 [1.035, 1.075]	3.78E-08	+ + + + + +
rs209215	<i>ZNF280C</i>	intronic	130,251,839	T	C	1,145,797	39.90%	1.048 [1.028, 1.069]	2.70E-06	+ ? + + + +
rs5975709 †	<i>MAP7D3</i>	intronic	136,256,153	C	T	1,145,797	43.25%	0.953 [0.935, 0.972]	1.02E-06	- ? - - - -
rs5930938 †	<i>ADGRG4</i>	intronic	136,380,525	T	C	733,616	32.62%	0.943 [0.921, 0.965]	7.55E-07	- ? - ? - -
rs146964414	<i>MTM1</i>	intronic	150,608,170	T	C	1,152,184	8.23%	1.096 [1.060, 1.133]	8.10E-08	+ - + + + +

885

886 ‡ The odds ratios are reported with regard to a single active allele. In women, due to random XCI, the relative risk conferred would be half that
887 reported here.

888 † Rs5975709 was the lead variant in its respective locus, but it had no association results in ADSP and FinnGen. The second most significant variant
889 in this locus, rs5930938, did have association results in FinnGen and was therefore additionally listed to provide additional insight.

890 *Abbreviations: OR, odds ratio; CI, confidence interval; EA, effect allele; OA, other allele; EAF, effect allele frequency; BP, base pair; No., number.*

891 **Table 2. Genetic colocalization with quantitative trait locus data.** Colocalization was evaluated for genes in each AD associated locus using a 2Mb
892 window centered on the lead variant. Evidence for colocalization was considered at colocalization posterior probability (PP4)>0.7 (bolded). The
893 table presents PP4 results and is restricted to genes and datasets/tissues where at least one colocalization reached PP4>0.7. As such, the table is
894 partitioned into 4 common variant loci that showed colocalization support. Bolded entries with an asterisk (*) indicate the lead variant was also a
895 significant QTL in the respective data/tissue. Missing entries indicate that no QTL data were available. The total number of times a gene was
896 prioritized (PP4>0.7) is summarized to help identify the most likely causal gene per locus (blue bolded genes and numbers). Overlapping datasets
897 were considered as those where subjects partially or fully overlapped (non-overlapping datasets are separated by dashed lines).

Dataset	Tissue	QTL	SLC9A7							ZNF280C				ADGRG4					MTM1				
			ENSG00000286306	KRBOX4	CHST7	SLC9A7	RP2	JADE3	UBA1	ELK1	ELF4	AIFM1	ZNF280C	RBMX2	FHL1	MAP7D3	BRS3	HTATSF1	ALG83813.2	MTMR1			
Wingo et al. 2023 (AD Knowledge Portal)	Brain - Dorsolateral prefrontal cortex	pQTL				0.56	0.89*		0.05					0.02				0.12	0.05	0.03		0.01	
Wingo et al. 2023 (AD Knowledge Portal)	Brain - Dorsolateral prefrontal cortex	eQTL		0.77*	0.95*	0.56	0.04	0.70*	0.04	0.00				0.16	0.45	0.00		0.78*	0.93*		0.05	0.05	
CommonMind (eQTL Catalogue)	Brain - Dorsolateral prefrontal cortex	eQTL	0.88	0.04	0.92*	0.86*	0.07	0.07	0.93*	0.04			0.05	0.12	0.09	0.29		0.13	0.92*	0.04	0.03	0.16	
GTEx	Brain - (9 brain areas)	eQTL		0.74	0.86*	0.64	0.13	0.51	0.12	0.33			0.11	0.56	0.77*	0.07		0.10	0.77*	0.04	0.04	0.07	0.88
GTEx	Whole blood	eQTL		0.23	0.20	0.39	0.03	0.06	0.07	0.03			0.02	0.19	0.05	0.02		0.02	0.92*		0.01	0.02	0.01
GTEx	Other (20 tissues not brain or blood)	eQTL		0.92	0.71	0.98*	0.14	0.76	0.10	0.16			0.78*	0.78*	0.92*	0.77		0.13	0.89*	0.73	0.87*	0.77	0.79
Fairfax et al. 2014 (eQTL Catalogue)	Monocytes (4 conditions)	eQTL		0.10	0.27	0.93*	0.50	0.10	0.13	0.86			0.01	0.73	0.19	0.04		0.85	0.13	0.04	0.07	0.18	
CEDAR (eQTL Catalogue)	Monocytes	eQTL		0.05	0.15	0.93*	0.05	0.43	0.12	0.08			0.06	0.78*	0.04	0.05		0.29	0.08	0.04	0.06	0.11	
No. times prioritized across datasets & tissues			1	4	10	12	1	2	1	1			1	6	17	1		2	10	1	2	1	2
No. times prioritized in non-overlapping datasets			1	2	3	4	1	2	1	1			1	3	1	1		2	3	1	1	1	1

898

899 *Abbreviations: QTL, quantitative trait locus; eQTL, expression quantitative trait locus; pQTL, protein quantitative trait locus; No., number.*